LONDON--(BUSINESS WIRE)--The global tardive dyskinesia treatment market 2019-2023 is expected to post a CAGR of more than 4% during the forecast period, according to the latest market research report ...

DelveInsight’s Dyskinesia Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major ...

Currently there are two FDA approved treatment options for tardive dyskinesia. There are two medications that are VMAT2 inhibitors. These are valbenazine (Ingrezza) and deutetrabenazine (Austedo) made ...

Study reveals over half of long-term care residents with tardive dyskinesia do not receive standard treatment, highlighting care gaps. Less than half of patients diagnosed with tardive dyskinesia in ...

In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.

-- Patients enrolled in the pivotal trials increased daily ON time without dyskinesia by 2.9 hours with GOCOVRI compared to placebo, through the reduction of both OFF time and dyskinesia - -- GOCOVRI ...

DelveInsight’s, “Primary Ciliary Dyskinesia – Pipeline Insight, 2025,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape.

You can check In-Detail TOC from here: https://marketresearch.biz/report/tardive-dyskinesia-treatment-market/ Get Full PDF Sample Copy of Report (Including Full TOC ...

Patients on antipsychotics need to be regularly monitored for signs of tardive dyskinesia, a medication-induced movement disorder diagnosed when the involuntary movements persist for at least a month ...

The Business Research Company's Tardive Dyskinesia Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Get 30% Off All Global Market Reports With Code ONLINE30 – ...